NeoGenomics Inc. Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 24.3× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Vanguard Short Term Corporate Bond ETF for 54 Days on average.
| NEO | VCSH | |
|---|---|---|
Market Cap | $2.14B | $51.90B |
Volume | 2,228,400 | 4,498,428 |
Sector | Health | Fixed Income |
52-Week High | $19.91 | $80.20 |
52-Week Low | $7.19 | $77.03 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $2.44B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCSH trades at $77.32, down 0.05% with a bearish technical signal. The ETF offers a competitive yield around 4.5% with a short 2.7-year duration, providing stability amid rising rates. Recent news highlights VCSH's lower expense ratio of 0.03% compared to peers and its focus on investment-grade corporate bonds. However, technical indicators show selling pressure with RSI at overbought levels and bearish moving average signals.
The outlook remains cautious due to tight credit spreads and limited price appreciation potential. While VCSH provides higher yield than treasury alternatives, it carries greater credit risk. Recent institutional activity shows mixed sentiment with both position increases and decreases reported. The ETF's short duration minimizes interest rate risk but faces headwinds from compressed spreads and competitive pressure from broader bond ETFs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →